Literature DB >> 18287290

Assessment of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever.

Michael Ellis1, Basel Al-Ramadi2, Malcolm Finkelman3, Ulla Hedstrom4, Jorgen Kristensen5, Hussein Ali-Zadeh5, Lena Klingspor6.   

Abstract

The performance of the Fungitell assay was investigated in 100 patients with haematological malignancy undergoing chemotherapy who developed antibiotic-unresponsive neutropenic fever (AUNF). Serum beta-D-glucan (BG) concentrations were significantly elevated on the first day of AUNF and all subsequent alternate days to day 10 in 38 patients who developed an invasive fungal infection (IFI) compared to 42 patients remaining free of such infections. The mean and median values of BG were 171.9+/-29.6 and 95.8 pg ml(-1), respectively, for patients with IFI and 64.4+/-17.1 and 32.9 pg ml(-1) for patients with only AUNF (P<0.0001). The differences remained significant over the 10 days despite antifungal therapy. The occurrence of > or =2 sequential concentrations of > or =80 pg ml(-1) ('positive' test) was found to give the best overall option for diagnosis, with an accuracy of 81.3%, sensitivity of 86.8%, positive predictive value of 76.7% and negative predictive value of 86.5%. Of the patients with an IFI, 78% developed a positive test at or before the clinical diagnosis was made -- this occurred at a mean (range) of 1.25 (-14 to +14) days prior to the IFI diagnosis. By starting sampling of blood from the first day of neutropenia rather than from the first day of AUNF, 50% of the patients with subsequent IFI would have been identified 5 days earlier. Increasing sampling to daily from alternate-day frequency did not further improve this earlier timing of an IFI diagnosis. A greater proportion of patients with persistent high levels of BG without overt IFI had severe enterocyte damage or mucositis than those with lower levels of BG without IFI (P=0.002). If the results of the initial BG test had been acted on to change antifungal therapy, discontinuation would have been inappropriate in 30% of patients and would have delayed definitive antifungal therapy. Although the findings for the cohort of patients studied are very useful, there is inter-patient variability in the test's performance. An holistic diagnostic approach is therefore necessary to interpret the test results optimally. Future studies should address this in further detail as well as the impact of empirical antifungal drug use and patient outcome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18287290     DOI: 10.1099/jmm.0.47479-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  38 in total

1.  Early diagnosis and preemptive therapy of pulmonary mold infections in high-risk patients.

Authors:  Johan Maertens; Griet Huysmans; Koen Theunissen
Journal:  Curr Infect Dis Rep       Date:  2008-11       Impact factor: 3.725

2.  β-D-Glucan Screening for Detection of Invasive Fungal Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Antonia Koltze; Peter Rath; Stefan Schöning; Jörg Steinmann; Thomas A Wichelhaus; Peter Bader; Konrad Bochennek; Thomas Lehrnbecher
Journal:  J Clin Microbiol       Date:  2015-06-03       Impact factor: 5.948

3.  The Role of Biomarkers for Diagnosis of and Therapeutic Decisions Related to Invasive Aspergillosis in Children.

Authors:  Brian T Fisher
Journal:  Curr Fungal Infect Rep       Date:  2013-03-01

4.  How to interpret serum levels of beta-glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: optimal cut-off levels and confounding factors.

Authors:  H Hammarström; N Kondori; V Friman; C Wennerås
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-01-09       Impact factor: 3.267

Review 5.  Management of invasive candidiasis in nonneutropenic ICU patients.

Authors:  Emmanuel Weiss; Jean-François Timsit
Journal:  Ther Adv Infect Dis       Date:  2014-10

Review 6.  Invasive Candida Infections in the ICU: Diagnosis and Therapy.

Authors:  Péter Hankovszky; Domokos Társy; Nándor Öveges; Zsolt Molnár
Journal:  J Crit Care Med (Targu Mures)       Date:  2015-11-10

7.  Interference of confounding factors on the use of (1,3)-beta-D-glucan in the diagnosis of invasive candidiasis in the intensive care unit.

Authors:  G Lo Cascio; R Koncan; G Stringari; A Russo; A Azzini; A Ugolini; M Ligozzi; E Polati; G Cornaglia; E Concia; V Schweiger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-13       Impact factor: 3.267

8.  Levels of (1→3)-β-D-glucan, Candida mannan and Candida DNA in serum samples of pediatric cancer patients colonized with Candida species.

Authors:  Eiman Mokaddas; Mona H A Burhamah; Zia U Khan; Suhail Ahmad
Journal:  BMC Infect Dis       Date:  2010-10-06       Impact factor: 3.090

9.  Bloodstream infections are an improbable cause of positive serum (1,3)-β-D-glucan in hematology patients.

Authors:  E Furfaro; M Mikulska; V Del Bono; F Guolo; P Minetto; M Gobbi; A Ghiso; A Bacigalupo; C Viscoli
Journal:  Clin Vaccine Immunol       Date:  2014-07-02

10.  Use and limits of (1-3)-β-d-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis.

Authors:  Annie Sulahian; Raphael Porcher; Anne Bergeron; Sophie Touratier; Emmanuel Raffoux; Jean Menotti; Francis Derouin; Patricia Ribaud
Journal:  J Clin Microbiol       Date:  2014-04-16       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.